Sichenzia Ross Ference LLP Represents BriaCell Therapeutics Corp. in $27.2 Million Private Placement
Press Release – New York, New York – June 8, 2021 – Sichenzia Ross Ference LLP announced today that it represented BriaCell Therapeutics Corp. (NASDAQ: BCTX), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, in a private placement offering. The offering consisted of (i) 4,370,343 common shares at a purchase price of US$5.26, (ii) 800,000 pre-funded common share purchase warrants at a purchase price of US$5.25 (exercisable at any time after the date of issuance at an exercise price of US$0.01 per common share) and (iii) 5,170,343 warrants to purchase up to 5,170,343 common shares. The gross proceeds were approximately $27.2 million.
ThinkEquity, a division of Fordham Financial Management, Inc., acted as the exclusive placement agent for the offering.
The Sichenzia Ross Ference LLP team was led by partners Gregory Sichenzia, Avital Perlman, Arthur Marcus, Marcelle Balcombe and law clerk Zachary Weiss.
- Sichenzia Ross Ference LLP Announces Over 80 Capital Markets Transactions Valued Over $2 Billion at the Closing of 2021 - January 13, 2022
- Sichenzia Ross Ference LLP Adds Two Key Additions to its Corporate and Securities Law Team - January 11, 2022
- Sichenzia Ross Ference LLP Represents Aegis Capital Corp. in $9.8 Million Underwritten Offering of BiondVax Pharmaceuticals Ltd. - December 30, 2021